Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of viral infections, cancer, and inflammatory diseases
today announced the presentation of scientific data relating to its
novel, proprietary STING (
STimulator of
INterferon
Genes) agonist
compound, SB 11285, at the American Association for Cancer Research
(AACR) Special Conference on Tumor Immunology and Immunotherapy
taking place on October 20-23, 2016 at the Boston Marriott Copley
Place in Boston, MA.
“The data presented at this year’s AACR Special
Conference on Tumor Immunology and Immunotherapy are important
because they provide compelling early scientific evidence
supporting the further development of SB 11285 as a potential novel
immunotherapeutic agent in the treatment of various cancers,”
stated Radhakrishnan (Kris) Iyer, PhD, Chief Scientific Officer of
Spring Bank. “Among the key pre-clinical findings were that SB
11285 is a highly potent STING agonist that causes the induction of
Interferons (IFN), NF-KB, Interferon-stimulating genes (ISGs),
cytokines, and pattern recognition receptors (PRRs). SB 11285 was
also shown to cause apoptosis of multiple tumor-derived cell
lines.”
Dr. Iyer continued, “Immunotherapy has emerged as a
transformative approach for the treatment of cancer; nevertheless,
many patients remain unresponsive to treatment. It is being
recognized that induction of type I interferons (IFN) and
interferon-stimulated genes (ISGs) in tumor cells and within the
tumor microenvironment (TME) is essential for modulating the
host-immune response for amplifying anti-tumor response. We plan to
continue the development of SB 11285 in an effort to potentially
demonstrate that this novel agent could be an important addition to
current standard of care in the treatment of various cancers and
hope to increase the treatment responses in patients.“
A summary of the data presented by Spring Bank’s
scientists Dr. Shenghua Zhou and Dr. Rupa Challa at the AACR
Special Conference on Tumor Immunology and Immunotherapy is
described below:
Poster Presentations
Poster Title: Novel dinucleotides
that activate STING signaling for Immuno-oncologyDate and
Time: Saturday, October 22, 2016, 6:15 – 8:45
pmPoster Session: Poster Session BBoard
Number: B39Session Location: Back Bay
Results: Through in vitro assays
in conjunction with Structure Activity Relationship studies, we
have identified potent compounds that activate cGAS-STING signaling
pathway for induction of IRF, IFN, and NF-KB. These compounds also
cause induction of expression of PRRs, including RIG-I, MDA-5,
LGP2, as well as, ISG54 and OAS-1.
Conclusion: We have discovered
potent, first-in-class agents that cause induction of IFN, NF-KB,
ISGs, and PRRs. Further optimization and preclinical evaluation of
the compounds for application in immuno-oncology is underway.
Poster Title: Nucleotide analogs
as Novel STING agonists for Immuno-oncologyDate and
Time: Saturday, October 22, 2016, 6:00 – 8:45 pm
Poster Session: Poster Session BBoard
Number: B40Session Location: Back
Bay
Results: Through in vitro assays
in conjunction with Structure Activity Relationship (SAR) studies,
we have identified several highly potent and selective
first-in-class STING agonists. A promising lead nucleotide compound
SB 11285 caused STING-dependent induction of: (a)
IRF with an EC50 of 2 nM that is 1000-fold more potent than the
natural STING agonist 2’,3’-cGAMP, (b) NF-KB with
an EC50 of 200 nM that is >200-fold more potent than
2’,3’-cGAMP, (c) selective apoptosis of human
monocyte leukemic cell lines (CC50, 500 nM) as compared to normal
PBMCs through induction of IFN, and NF-KB signaling, and
(d) expression of various PRRs and ISGs including
RIG-I, MDA-5, LGP2, ISG54 and OAS-1, as well as, PDL1 and PDL2.
Finally, SB 11285 showed potent in vitro anti-tumor activity in
multiple tumor cell lines.
Conclusion: We have discovered
highly potent first-in-class STING agonists that show excellent
selectivity in induction of IFN, NF-KB, ISGs, and PRRs, and
apoptosis of tumor-derived cell lines. The lead STING agonist SB
11285 has potent immune-modulating, as well as, anti-tumor
activities and is being advanced for additional preclinical studies
for application in immuno-oncology.
About Spring Bank
Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage
biopharmaceutical company engaged in the discovery and development
of a novel class of therapeutics using its proprietary small
molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH
compounds are small segments of nucleic acids that the company
designs to selectively target and modulate the activity of specific
proteins implicated in various disease states. The company is
developing its most advanced SMNH product candidate, SB 9200, for
the treatment of viral diseases, including hepatitis B virus. SB
9200 has been designed to selectively activate within infected
cells the cellular proteins, retinoic acid-inducible gene 1, or
RIG-I, and nucleotide-binding oligomerization domain-containing
protein 2, or NOD2, which have been implicated in the body’s immune
response to viral infections. Spring Bank believes that SB 9200 may
play an important role in antiviral therapy by modulating the
body’s immune response through its mechanisms of action to fight
viral infections such as HBV. For more information please visit:
www.springbankpharm.com.
Safe Harbor Statement:Any
statements in this press release about Spring Bank's future
expectations, plans and prospects, including statements about
Spring Bank's financial prospects, future operations and
sufficiency of funds for future operations, clinical development of
Spring Bank's product candidates, expectations regarding future
clinical trials and future expectations and plans and prospects for
Spring Bank and other statements containing the words "believes,"
"anticipates," "estimates," "expects," "intends," "plans,"
"predicts," "projects," "targets," "may," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
whether Spring Bank's cash resources will be sufficient to fund its
continuing operations for the periods anticipated; whether results
obtained in clinical trials will be indicative of results obtained
in future clinical trials; whether Spring Bank's product candidates
will advance through the clinical trial process on a timely basis;
whether the results of such trials will warrant submission for
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether Spring Bank's
product candidates will receive approval from regulatory agencies
on a timely basis or at all; whether, if product candidates obtain
approval, they will be successfully distributed and marketed; and
other factors discussed in the "Risk Factors" section of Spring
Bank's quarterly report on Form 10-Q for the quarter ended June 30,
2016, which is on file with the SEC, and in other filings Spring
Bank makes with the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
Spring Bank's views as of the date hereof. Spring Bank anticipates
that subsequent events and developments will cause Spring Bank's
views to change. However, while Spring Bank may elect to update
these forward-looking statements at some point in the future,
Spring Bank specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Spring Bank's views as of any date subsequent to the
date hereof.
Contact:
Jon Freve
Chief Financial Officer
Spring Bank Pharmaceuticals
(508) 473-5993
jfreve@springbankpharm.com
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Apr 2023 to Apr 2024